AION

AION Labs Launches CombinAble.AI to Reduce Time and Cost of Targeted Antibody Design, Advancing Optimization of Drug Development

Retrieved on: 
Tuesday, March 12, 2024
Knowledge, Cancer registry, AI, Doctor of Philosophy, AION, Safety, Therapy, Lead, Medical device

REHOVOT, Israel, March 12, 2024 /PRNewswire/ -- AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the launch of CombinAble.AI. The new startup has been created to address the challenges associated with antibody design in order to enhance and accelerate the development of more effective therapeutics.

Key Points: 
  • CombinAble was formed following an AION Labs' startup challenge aimed at developing an AI solution for the optimization of therapeutic antibodies.
  • Antibody optimization is a critical step in the drug development pipeline, transforming a preliminary functional antibody hit into a clinical drug candidate by enhancing multiple characteristics related to its safety, efficacy, and manufacturability.
  • CombinAble is the latest startup launched by AION Labs, through the investment and support of global pharmaceutical and technology leaders.
  • "The launch of CombinAble heralds a shift in the approach to targeted antibody design by leveraging AI to optimize and expedite the discovery process," said Mati Gill, CEO of AION Labs.

AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules

Retrieved on: 
Tuesday, February 20, 2024
Merck, Amazon Web Services, Chemistry, AI, RNA, Invention, AION, BioMed Central, Research, AWS, Vaccine

REHOVOT, Israel and HEIDELBERG, Germany, Feb. 20, 2024 /PRNewswire/ -- AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its latest global call for applications to identify computational biologists, biomedical scientists and inventors to form a new startup at AION Labs' headquarters in Rehovot, Israel.

Key Points: 
  • AION Labs' next startup will focus on the development of an AI/ML computational platform to identify functional regions in RNA that can be targeted with small molecules.
  • However, recent developments have shown that RNA levels can be modulated using small molecules, which has resulted in several candidate drugs currently in clinical trials.
  • RNA targeting is an emerging field and small molecule discovery of RNA modulators remains a significant challenge.
  • Further details about this call for applications can be found on the AION Labs website: www.aionlabs.com .

AION Labs Launches New Startup Leveraging Machine Learning for Molecular Glue Discovery

Retrieved on: 
Tuesday, January 30, 2024
Disease, AION, Patient, Biology, Research, Deep learning, Amazon Web Services, Computational biology, BioMed Central, University, AI, Algorithm, AWS, Protein, Doctor of Philosophy, Machine learning, Merck, Treatment, Data science, Weizmann Institute of Science, Medical device

REHOVOT, Israel , Jan. 30, 2024 /PRNewswire/ -- AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the formation of TenAces Biosciences. TenAces is a startup developing a novel approach to discover new molecular glue therapies, leveraging machine learning  to enhance development of treatments for a range of conditions.

Key Points: 
  • TenAces is a startup developing a novel approach to discover new molecular glue therapies, leveraging machine learning  to enhance development of treatments for a range of conditions.
  • TenAces emerged from AION Labs' fifth startup challenge to develop an AI platform to identify naturally occurring protein interactions leading to targeted protein degradation.
  • The platform solution is expected to facilitate the discovery and development of molecular glue therapies for enhanced targeted protein degradation.
  • TenAces is taking a different approach, by applying machine learning to study the various interactions, protein pairs, and multi-dimensional features to predict new molecular glues.

AION Labs Welcomes Amiti as Strategic Partner to Accelerate Israel's Position as a Leading Hub for Transformative AI-Powered Drug Discovery Innovation

Retrieved on: 
Monday, January 8, 2024
Ecosystem, Partnership, Drug discovery, AstraZeneca, Health, De novo, Seed, AI, Merck, AION, Biophysics, Computational biology, Amazon Web Services

REHOVOT, Israel, Jan. 8, 2024 /PRNewswire/ -- AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today a new strategic partnership with Amiti Ventures, one of the leading early-stage venture capital firms in Israel. The partnership further strengthens the alliance of global leaders in pharma, biotech, and technology investment, expanding its offering as a venture studio and partner for new startups.

Key Points: 
  • "We thank Amiti for its vote of confidence in our model of innovation for groundbreaking AI and computational biotech ventures.
  • We further appreciate Amiti's recognition that Israel's ecosystem is poised to lead the world in bringing AI and biotech together to solve our biggest drug discovery challenges."
  • By joining forces with Amiti, AION Labs is enhancing its expertise and capabilities in the deep tech and computational technology domains, areas that are critical to the success of biotech innovation.
  • "We also have been amazed by the can-do spirit of the AION Labs team," added Rabinowitz.

Chinese automotive industry has overtaken to supercars

Retrieved on: 
Saturday, October 14, 2023
NEVS, Aion Hyper SSR, Aviation, Ferrari, Silicon, Quark, Huawei, Acceleration, 0 to 100 / The Catch Up, AION, Hyper, Rail transport, Lamborghini

Meanwhile, we are amazing to see that we can't see any western parts, all of parts of Hyper SSR are independently developed and manufactured in China.

Key Points: 
  • Meanwhile, we are amazing to see that we can't see any western parts, all of parts of Hyper SSR are independently developed and manufactured in China.
  • Previously, China has not a say in automotive manufacturing, which is controlled by Europe, Japan and America.
  • Recently, Huawei launched a premium 5G smartphone, which triggered a popular discussion on whether the Chinese tech giant can break through the US blockade on chip technologies.
  • China has demonstrated an increasing threat to the western NEV industry, it is time for the western NEV industry to get wary and take actions to follow our footprints.

Chinese automotive industry has overtaken to supercars

Retrieved on: 
Saturday, October 14, 2023
NEVS, Aion Hyper SSR, Aviation, Ferrari, Silicon, Multimedia, Quark, Huawei, Acceleration, 0 to 100 / The Catch Up, AION, Hyper, Rail transport, Lamborghini

Meanwhile, we are amazing to see that we can't see any western parts, all of parts of Hyper SSR are independently developed and manufactured in China.

Key Points: 
  • Meanwhile, we are amazing to see that we can't see any western parts, all of parts of Hyper SSR are independently developed and manufactured in China.
  • Previously, China has not a say in automotive manufacturing, which is controlled by Europe, Japan and America.
  • Recently, Huawei launched a premium 5G smartphone, which triggered a popular discussion on whether the Chinese tech giant can break through the US blockade on chip technologies.
  • China has demonstrated an increasing threat to the western NEV industry, it is time for the western NEV industry to get wary and take actions to follow our footprints.

GAC MOTOR CELEBRATES AION Y LAUNCH IN JORDAN, MARKING CONTINUED SUCCESS IN EV MARKET

Retrieved on: 
Tuesday, September 26, 2023
AION, GAC, NEDC, Popular Executive Committee of Valencia, SUV, EV, GAC Motor, HP, Executive Committee, Electric motor

GUANGZHOU, China, Sept. 26, 2023 /PRNewswire/ -- GAC MOTOR is thrilled to announce the launch of the highly anticipated AION Y compact electric SUV in Jordan.

Key Points: 
  • GUANGZHOU, China, Sept. 26, 2023 /PRNewswire/ -- GAC MOTOR is thrilled to announce the launch of the highly anticipated AION Y compact electric SUV in Jordan.
  • Wang Dan, Director of the Executive Committee, extended heartfelt congratulations for the successful introduction of the AION Y in the Jordanian market.
  • The launch of the AION Y in Jordan marks an exciting chapter in GAC MOTOR's journey, reaffirming its dedication to transforming the global automotive landscape.
  • GAC MOTOR's unwavering commitment to sustainability, innovation, and customer satisfaction continues to drive its success in the global market.

AION Receives FDA Clearance for Its iTempShield Skin-Wearable Device and Software Platform for Professional and Retail Environments

Retrieved on: 
Wednesday, August 30, 2023
Medical Devices, Health Technology, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, Infection, Learning, CMS, IV, CPT, Thermometer, Health care, Food, Food and Drug Administration, Cancer, Temperature, Sale, Sepsis, AION, Thermoregulation, Death, Hospital, City, BioSystems, Patient, Risk, ICU, Immunodeficiency, FDA, Skin, Ellis, Medical device, Pharmaceutical industry

AION Biosystems will primarily focus on early infection detection in cancer patients and long-term care residents.

Key Points: 
  • AION Biosystems will primarily focus on early infection detection in cancer patients and long-term care residents.
  • Unlike any other skin-applied wearable, the low-profile iTempShield adheres to the surface of the skin of the chest.
  • AION architected the platform to easily integrate into hospital or physician medical records systems and remote patient monitoring systems.
  • Healthcare providers interested in learning more about the remote monitoring device and platform can contact [email protected] or visit the company’s website for more information.

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development

Retrieved on: 
Thursday, June 29, 2023
Drug development, Failure, Research, VPE, AION, Standard of care, Patient, BioMed Central, Drug discovery, Sanofi, Pharmaceutical industry

Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development.

Key Points: 
  • Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development.
  • HEIDLEBERG, Germany, June 29, 2023 - (ACN Newswire) - BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: "Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates" (VPE).
  • The new research team will be led by Dr. Douglas McCloskey, a scientist and entrepreneur jointly selected by the Sanofi and BioMed X Institute management for the group leader position.
  • To learn more about this new AI-based research group, visit the BioMed X Institute website at www.bio.mx.

The Middle East Media Delegation Visits GAC and applauds the Strength of "Technology GAC"

Retrieved on: 
Monday, July 24, 2023
GAC Motor, Marketing, City, Xi, GAC Group, Jordan, AION, Three-Country Cairn, GAC, Growth, Dentsply Sirona, United Arab Emirates, Environmental remediation

Journalists from mainstream Middle East media came into GAC, experience the innovative strength of "Technology GAC".

Key Points: 
  • Journalists from mainstream Middle East media came into GAC, experience the innovative strength of "Technology GAC".
  • During the visit, the Middle East media delegation visited GAC Technology Museum, GAC MOTOR, AION and GAC R&D Center, and experience the star models of GAC MOTOR and AION.
  • During the visit, the delegation conducted in-depth exchanges with representatives from GAC on international business, GAC MOTOR's development in the Middle East, GAC product and technical advantages.
  • Zeng Hebin, General Manager of GAC International, said: "GAC EMZOOM and EMKOO will meet with consumers in Middle East countries.